TumCP Cancer Research Results

TumCP, Tumor Cell proliferation: Click to Expand ⟱
Source:
Type:
Tumor cell proliferation is a key characteristic of cancer. It refers to the rapid and uncontrolled growth of cells that can lead to the formation of tumors.
Scientific Papers found: Click to Expand⟱
1453- SFN,    Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumCG↓, TumCP↓, TumCCA↑, H3↑, H4↑, HDAC↓, CDK1↑, CDK2↑, p19↑, *BioAv↑,
1434- SFN,  GEM,    Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
- in-vitro, CCA, HuCCT1 - in-vitro, CCA, HuH28 - in-vivo, NA, NA
HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,
1509- SFN,    Combination therapy in combating cancer
- Review, NA, NA
NRF2↑, ChemoSideEff↓, eff↑, TumCP↓, Apoptosis↑, TumCCA↑, eff↑, PSA↓, P53↑, Hif1a↓, CAIX↓, chemoR↓, 5HT↓,
1475- SFN,  Form,    Combination of Formononetin and Sulforaphane Natural Drug Repress the Proliferation of Cervical Cancer Cells via Impeding PI3K/AKT/mTOR Pathway
- in-vitro, Cerv, HeLa
TumCP↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↑,
3326- SIL,    Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway
- in-vitro, Liver, HepG2 - in-vitro, Liver, Hep3B
*hepatoP↑, chemoPv↑, ChemoSen↑, TumCP↓, TumCMig↓, TumCI↓, Hif1a↓, VEGF↓, angioG↓,
3323- SIL,    Anticancer therapeutic potential of silibinin: current trends, scope and relevance
- Review, Var, NA
Inflam↓, angioG↓, antiOx↑, TumMeta↓, TumCP↓, TumCCA↑, TumCD↑, α-SMA↓, p‑Akt↓, p‑STAT3↓, COX2↓, IL6↓, MMP2↓, HIF-1↓, Snail↓, Slug↓, Zeb1↓, NF-kB↓, p‑EGFR↓, JAK2↓, PI3K↓, PD-L1↓, VEGF↓, CDK4↓, CDK2↓, cycD1/CCND1↓, E2Fs↓,
3646- SIL,    "Silymarin", a promising pharmacological agent for treatment of diseases
- Review, NA, NA
*P-gp↓, *Inflam↓, *hepatoP↑, *antiOx↑, *GSH↑, *BioAv↑, *SOD↑, *IFN-γ↓, *IL4↓, *IL10↓, *Half-Life↓, *TNF-α↓, *ALAT↓, *AST↓, Akt↓, chemoP↑, β-catenin/ZEB1↓, TumCP↓, MMP↓, Cyt‑c↑, *RenoP↑, *BBB↑,
3305- SIL,    Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vivo, NA, NA
TumCP↓, tumCV↓, BAX↑, cl‑PARP↑, Casp9↑, p‑JNK↑, Bcl-2↓, p‑p38↓, p‑ERK↓, *toxicity∅, Dose↝, *hepatoP↑, Inflam↓, AntiCan↑,
3297- SIL,  Rad,    Studies on radiation sensitization efficacy by silymarin in colon carcinoma cells
- in-vitro, CRC, HCT15 - in-vitro, CRC, RKO
TumCP↓, RadioS↑, TumCCA↑, DNAdam↓, MMP↓, ROS↓, *radioP↑,
3296- SIL,    Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway
- in-vitro, Oral, Ca9-22 - in-vivo, Oral, YD10B
TumCP↓, TumCCA↑, ROS↑, SOD1↓, SOD2↓, *JNK↑, toxicity?, TumCMig↓, TumCI↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, P53↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, SOD↓,
1140- SIL,    Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth
- in-vitro, PC, AsPC-1 - in-vivo, PC, NA - in-vitro, PC, MIA PaCa-2 - in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3
TumCG↓, Glycolysis↓, cMyc↓, STAT3↓, TumCP↓, Weight∅, Strength↑, DNAdam↑, Casp3↑, Casp9↑, GLUT1↓, HK2↓, LDHA↓, GlucoseCon↓, lactateProd↓, PPP↓, Ki-67↓, p‑STAT3↓, cachexia↓,
1127- SIL,    Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1
- in-vitro, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, EMT↓, RHBDD1↓,
964- SIL,    Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics
- vitro+vivo, Pca, LNCaP - in-vitro, Pca, 22Rv1
TumCP↓, Hif1a↓, NADPH↓, angioG↓, FASN↓, ACC↓,
978- SIL,    A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment
- Review, NA, NA
PI3K↓, Akt↓, NF-kB↓, Wnt/(β-catenin)↓, MAPK↓, TumCP↓, TumCCA↑, Apoptosis↑, p‑EGFR↓, JAK2↓, STAT5↓, cycD1/CCND1↓, hTERT/TERT↓, AP-1↓, MMP9↓, miR-21↓, miR-155↓, Casp9↑, BID↑, ERK↓, Akt2↓, DNMT1↓, P53↑, survivin↓, Casp3↑, ROS↑,
2417- SK,    Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H446
TumCP↓, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, PFKFB2↓, Warburg↓, GLUT1∅, LDHA∅, PKM2∅, GLUT3∅, PDH∅,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
2360- SK,    Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway
- in-vitro, NPC, HONE1 - in-vitro, NPC, SUNE-1
TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, ATP↓, PKM2↓, PI3K↓, Akt↓, MMP3↓, MMP9↓, TIMP1↑,
2234- SK,    Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1
- in-vitro, GC, NA
TumCP↓, TumCI↓, TumCMig↓, cMyc↓, YAP/TEAD↓,
2198- SK,    Shikonin suppresses proliferation of osteosarcoma cells by inducing ferroptosis through promoting Nrf2 ubiquitination and inhibiting the xCT/GPX4 regulatory axis
- in-vitro, OS, MG63 - in-vitro, OS, 143B
TumCP↓, TumCCA↑, Ferroptosis↑, Iron↑, ROS↑, lipid-P↑, MDA↑, mtDam↑, NRF2↓, xCT↓, GPx4↓, GSH/GSSG↓, Keap1↑,
2195- SK,    Shikonin induces ferroptosis in osteosarcomas through the mitochondrial ROS-regulated HIF-1α/HO-1 axis
- in-vitro, OS, NA
TumCP↓, Ferroptosis↓, Hif1a↑, HO-1↑, Iron↑, ROS↑, GSH/GSSG↓, GPx4↓,
2192- SK,    Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation
- in-vitro, ESCC, KYSE-510 - in-vitro, ESCC, Eca109 - in-vivo, NA, NA
TumCP↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, p‑PKM2↓, p‑STAT3↓, GLUT1↓, HK2↓, TumW↓,
2190- SK,    Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway
- in-vitro, HCC, HCCLM3
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, MMP↓, ROS↑, OCR↓, ATP↓, PKM2↓,
2182- SK,  Cisplatin,    Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway
- in-vitro, Lung, A549 - in-vitro, Lung, PC9 - in-vivo, NA, NA
tumCV↓, TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, PKM2↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, ChemoSen↑, TumVol↓, TumW↓, GLUT1↓,
2203- SK,    Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation
- in-vitro, Lung, NA
TumCP↓, Apoptosis↓, TumCMig↓, TumCI↓, Ferroptosis↑, ERK↓, GPx4↓, 4-HNE↑, ROS↑, GSH↓, ATF3↑, HDAC1↓, ac‑Histones↑,
2229- SK,    Shikonin induces apoptosis and prosurvival autophagy in human melanoma A375 cells via ROS-mediated ER stress and p38 pathways
- in-vitro, Melanoma, A375
Apoptosis↑, TumAuto↑, TumCP↓, TumCCA↑, P21↑, cycD1/CCND1↓, ER Stress↑, p‑eIF2α↑, CHOP↑, cl‑Casp3↑, p38↑, LC3B-II↑, Beclin-1↑, ROS↑, eff↓,
2227- SK,    Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species
- in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901 - in-vitro, Nor, GES-1
selectivity↑, TumCP↓, TumCD↑, ROS↑, MMP↓, Casp↑, Cyt‑c↑, Endon↑, AIF↑, eff↓, ChemoSen↑, TumCCA↑, GSH/GSSG↓, lipid-P↑,
2221- SK,    Shikonin Induces Apoptosis, Necrosis, and Premature Senescence of Human A549 Lung Cancer Cells through Upregulation of p53 Expression
- in-vitro, Lung, A549
Apoptosis↑, TumCP↓, tumCV↓, Necroptosis↑, P53↑, ROS↑, NF-kB↓,
3051- SK,    Resveratrol mediates its anti-cancer effects by Nrf2 signaling pathway activation
- Review, Var, NA
Nrf1↑, Apoptosis↑, TumCP↓, eff⇅, chemoP↑, eff↑, VCAM-1↓, Hif1a↓,
3044- SK,    Shikonin Inhibits Non-Small-Cell Lung Cancer H1299 Cell Growth through Survivin Signaling Pathway
- in-vitro, Lung, H1299 - in-vitro, Lung, H460
TumCP↓, survivin↓, TumCCA↓, CDK2↓, CDK4↓, XIAP↓, Casp3↑, Casp9↑, cycD1/CCND1↓, cycE/CCNE↓,
3041- SK,    Promising Nanomedicines of Shikonin for Cancer Therapy
- Review, Var, NA
Glycolysis↓, TAMS↝, BioAv↓, Half-Life↝, P21↑, ERK↓, ROS↑, GSH↓, MMP↓, TrxR↓, MMP13↓, MMP2↓, MMP9↓, SIRT2↑, Hif1a↓, PKM2↓, TumCP↓, TumMeta↓, TumCI↓,
3046- SK,    Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway
- in-vitro, Lung, A549
TumCP↓, TumCI↓, TumCMig↓, p‑ERK↓, ITGB1↓,
965- SK,    Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW-620
Hif1a↓, ROS↓, mTOR↓, p70S6↓, 4E-BP1↓, eIF2α↓, TumCCA↑, TumCP↓, Half-Life↝,
1073- SK,  Chemo,    Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells
- in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3
PAK1↓, TumCP↓, Apoptosis↑, ChemoSen↑, ROS↑,
5103- SK,    Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor
- in-vitro, NSCLC, A549
CSCs↓, TumCP↓, Nanog↓, OCT4↓, p‑Akt↓, P70S6K↓, PI3K↓, mTOR↓, eff↑,
5101- SK,    Shikonin induces colorectal carcinoma cells apoptosis and autophagy by targeting galectin-1/JNK signaling axis
- vitro+vivo, CRC, SW-620 - vitro+vivo, CRC, HCT116
Apoptosis↑, TumAuto↑, Gal1↑, TumCP↓, ROS↑, eff↑,
5100- SK,    Shikonin-induced necroptosis in nasopharyngeal carcinoma cells via ROS overproduction and upregulation of RIPK1/RIPK3/MLKL expression
- vitro+vivo, NPC, NA
TumCP↓, RIP1↑, ROS↑, Necroptosis↑, Casp3↑, Casp8↑, eff↓, TumCG↓,
5104- SK,    Shikonin induces cell cycle arrest in human gastric cancer (AGS) by early growth response 1 (Egr1)-mediated p21 gene expression.
- in-vitro, GC, AGS
TumCP↓, TumCCA↑, P21↑,
1195- SM,    Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF-κB signaling pathways
- in-vitro, Lung, A549 - in-vitro, Liver, HepG2 - in-vitro, CRC, HCT116
T-Cell↑, TumCP∅, IL4↑, IL6↑, IFN-γ↑, TLR4↑, TLR1↑, TLR2↑, p‑JNK↑, p‑ERK↑, IKKα↑,
1291- SM,    Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCCA↑, BAX↑, Bcl-2↓,
4891- Sper,    Spermidine as a promising anticancer agent: Recent advances and newer insights on its molecular mechanisms
- Review, Var, NA - Review, AD, NA
TumCCA↑, TumCP↓, TumCG↓, *Inflam↓, *antiOx↑, *neuroP↑, *cognitive↑, *Aβ↓, *mitResp↑, AntiCan↑, TumCD↑, TumAuto↑, *AntiAge↑, LC3B-II↑, ATG5↑, Beclin-1↑, mt-ROS↑, H2O2↑, Apoptosis↑, *ROS↑, ChemoSen↑, MMP↓, Cyt‑c↑,
1062- SSE,    Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
- in-vitro, GBM, LN229 - in-vitro, GBM, T98G - in-vitro, GBM, U87MG
HDAC↓, TumCP↓, TumCCA↑, Apoptosis↑, Casp3↝, MMP2↓, *BioAv↝,
4739- SSE,  Chemo,  Rad,    Therapeutic Benefits of Selenium in Hematological Malignancies
- Review, Var, NA
ChemoSen↑, radioP↑, QoL↑, Risk↓, *selenoP↑, TumCP↓, Inflam↓, ChemoSen↑, TumCCA↑, Apoptosis↑, angioG↓, Dose⇅, ROS↑, eff↑, Risk↓, eff∅, CSCs↓, ROS↑,
4723- SSE,    Selenium Induces Ferroptosis in Colorectal Cancer Cells via Direct Interaction with Nrf2 and Gpx4
- in-vitro, CRC, HCT116
TumCP↓, Iron↑, MDA↑, ROS↑, MMP↓, NRF2↓, GPx4↓, Ferroptosis↑,
4718- SSE,    High-Dose Selenium Induces Ferroptotic Cell Death in Ovarian Cancer
- in-vitro, Ovarian, NA
TumCP↑, ROS↑, GPx↓, lipid-P↑, Ferroptosis↑, Dose↑,
5080- SSE,    Sodium Selenite Regulates the Proliferation and Apoptosis of Gastric Cancer Cells by Suppressing the Expression of LncRNA HOXB-AS1
- in-vitro, GC, HGC27 - in-vitro, GC, NCI-N87
AntiTum↑, HOXB-AS1↓, TumCP↓, TumCI↓, Apoptosis↑, BAD↓, Bcl-2↓, cl‑Casp3↑, MMP2↓, E-cadherin↑, N-cadherin↓, ROS↑, NF-kB↓,
5075- SSE,    Sodium selenite inhibits proliferation and metastasis through ROS‐mediated NF‐κB signaling in renal cell carcinoma
- vitro+vivo, RCC, 786-O
TumCP↓, TumCMig↓, Apoptosis↑, ROS↑, NF-kB↓, eff↓, E-cadherin↑, cl‑Casp3↑, VEGF↓, MMP9↓, EMT↓, MMP↓, mtDam↑, BAX↑, Bcl-2↓,
5091- SSE,    Superoxide-mediated ferroptosis in human cancer cells induced by sodium selenite
- in-vitro, GBM, U87MG - in-vitro, Cerv, HeLa - in-vitro, BC, MCF-7 - in-vitro, Pca, PC3 - in-vitro, CRC, HT-29 - in-vitro, Nor, SVGp12
Ferroptosis↑, xCT↓, GSH↓, GPx4↓, Iron↑, lipid-P↑, ROS↑, eff↓, TumCP↓, TumCD↑,
5090- SSE,    Sodium Selenite Induces Ferroptosis in Non-small Cell Lung Cancer A549 Cells Via Reactive Oxygen Species (ROS)/Glutathione (GSH)/Glutathione Peroxidase4 (GPx4) Axis
- NA, Lung, A549
TumCP↓, ROS↑, GSH↓, MMP↓, GPx4↓, Iron↑,
5088- SSE,    Superoxide-mediated ferroptosis in human cancer cells induced by sodium selenite
- in-vitro, BC, MCF-7 - in-vitro, GBM, U87MG - in-vitro, Pca, PC3 - in-vitro, Cerv, HeLa - in-vitro, GBM, A172
Ferroptosis↑, ROS↑, Iron↑, xCT↓, GSH↓, GPx4↓, lipid-P↑, TumCP↓, selectivity↑,
5331- TFdiG,    Anti-Cancer Properties of Theaflavins
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, cl‑PARP↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, BAX↑, Bcl-2↓, p‑Akt↓, p‑mTOR↓, PI3K↓, cMyc↓, P53↑, ROS↑, NF-kB↓, MMP9↓, MMP2↓, TumVol↓, PSA↓, TumCCA↑, VEGF↓, Hif1a↓, CDK2↓, CDK4↓, GSH↓, Dose↑, BioAv↓, BioAv↓, BioAv↑,

Showing Research Papers: 551 to 600 of 656
Prev Page 12 of 14 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 656

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

4-HNE↑, 1,   antiOx↑, 1,   ATF3↑, 1,   Ferroptosis↓, 1,   Ferroptosis↑, 6,   GPx↓, 1,   GPx4↓, 7,   GSH↓, 6,   GSH/GSSG↓, 3,   H2O2↑, 1,   HO-1↑, 1,   Iron↑, 6,   Keap1↑, 1,   lipid-P↑, 5,   MDA↑, 2,   NQO1?, 1,   Nrf1↑, 1,   NRF2↓, 2,   NRF2↑, 1,   ROS↓, 2,   ROS↑, 25,   mt-ROS↑, 1,   SOD↓, 1,   SOD1↓, 1,   SOD2↓, 1,   TrxR↓, 1,   TrxR1↓, 1,   xCT↓, 3,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↓, 2,   CDC25↓, 1,   MMP↓, 9,   mtDam↑, 2,   OCR↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACC↓, 1,   CAIX↓, 1,   cMyc↓, 3,   FASN↓, 1,   GlucoseCon↓, 5,   Glycolysis↓, 4,   ac‑Histones↑, 1,   HK2↓, 2,   lactateProd↓, 5,   LDHA↓, 1,   LDHA∅, 1,   NADPH↓, 1,   PDH∅, 1,   PFKFB2↓, 1,   PKM2↓, 6,   PKM2∅, 1,   p‑PKM2↓, 1,   PPP↓, 1,   SIRT2↑, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 5,   p‑Akt↓, 3,   Apoptosis↓, 1,   Apoptosis↑, 18,   ATF2↓, 1,   BAD↓, 1,   BAX↑, 6,   Bcl-2↓, 6,   BID↑, 1,   Casp↑, 1,   Casp3↑, 5,   Casp3↝, 1,   cl‑Casp3↑, 6,   cl‑Casp7↑, 1,   Casp8↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 4,   cl‑Casp9↑, 1,   p‑Chk2↑, 1,   Cyt‑c↑, 3,   Endon↑, 1,   Ferroptosis↓, 1,   Ferroptosis↑, 6,   GRP58↓, 1,   hTERT/TERT↓, 1,   p‑JNK↑, 3,   MAPK↓, 1,   Necroptosis↑, 3,   p38↑, 1,   p‑p38↓, 1,   p‑p38↑, 1,   RIP1↓, 1,   RIP1↑, 1,   survivin↓, 2,   TumCD↑, 4,   TUNEL↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

p70S6↓, 1,  

Transcription & Epigenetics ⓘ

H3↑, 1,   ac‑H3↑, 1,   H4↑, 1,   miR-21↓, 1,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   eIF2α↓, 1,   p‑eIF2α↑, 1,   ER Stress↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 2,   LC3B-II↑, 2,   TumAuto↑, 4,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,   DNAdam↑, 1,   DNMT1↓, 1,   P53↑, 5,   cl‑PARP↑, 4,  

Cell Cycle & Senescence ⓘ

CDK1↑, 1,   CDK2↓, 3,   CDK2↑, 1,   CDK4↓, 3,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 1,   E2Fs↓, 1,   p19↑, 1,   P21↑, 4,   TumCCA↓, 1,   TumCCA↑, 17,  

Proliferation, Differentiation & Cell State ⓘ

4E-BP1↓, 1,   CSCs↓, 2,   EMT?, 1,   EMT↓, 3,   ERK↓, 3,   p‑ERK↓, 3,   p‑ERK↑, 1,   HDAC↓, 3,   HDAC1↓, 1,   HOXB-AS1↓, 1,   mTOR↓, 4,   p‑mTOR↓, 1,   Nanog↓, 1,   OCT4↓, 1,   P70S6K↓, 1,   PI3K↓, 7,   Src↓, 1,   STAT3↓, 1,   p‑STAT3↓, 3,   STAT5↓, 1,   TumCG↓, 5,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

Akt2↓, 1,   AP-1↓, 1,   E-cadherin↑, 3,   FAK↓, 1,   ITGB1↓, 1,   Ki-67↓, 2,   miR-155↓, 1,   MMP13↓, 1,   MMP2↓, 5,   MMP3↓, 1,   MMP9↓, 5,   MMPs↓, 1,   N-cadherin↓, 2,   PAK1↓, 1,   RHBDD1↓, 1,   RIP3↓, 1,   Slug↓, 1,   Snail↓, 1,   TIMP1↑, 1,   TumCI↓, 13,   TumCMig↓, 13,   TumCP↓, 48,   TumCP↑, 1,   TumCP∅, 1,   TumMeta↓, 2,   VCAM-1↓, 1,   Vim↓, 1,   Zeb1↓, 1,   α-SMA↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   p‑EGFR↓, 2,   eNOS↓, 1,   HIF-1↓, 1,   Hif1a↓, 8,   Hif1a↑, 1,   TAMS↝, 1,   VEGF↓, 5,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 3,   GLUT1∅, 1,   GLUT3∅, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   Gal1↑, 1,   IFN-γ↑, 1,   IKKα↑, 1,   IL4↑, 1,   IL6↓, 1,   IL6↑, 1,   Inflam↓, 3,   JAK2↓, 2,   NF-kB↓, 6,   PD-L1↓, 1,   PSA↓, 2,   T-Cell↑, 1,   TLR1↑, 1,   TLR2↑, 1,   TLR4↑, 1,  

Synaptic & Neurotransmission ⓘ

5HT↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 1,   chemoR↓, 1,   ChemoSen↑, 8,   Dose↑, 2,   Dose⇅, 1,   Dose↝, 1,   eff↓, 5,   eff↑, 7,   eff⇅, 1,   eff∅, 1,   Half-Life↝, 2,   RadioS↑, 1,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

p‑EGFR↓, 2,   hTERT/TERT↓, 1,   IL6↓, 1,   IL6↑, 1,   Ki-67↓, 2,   PD-L1↓, 1,   PSA↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 4,   AntiTum↑, 1,   cachexia↓, 1,   chemoP↑, 2,   chemoPv↑, 1,   ChemoSideEff↓, 1,   QoL↑, 1,   radioP↑, 1,   Risk↓, 2,   Strength↑, 1,   toxicity?, 1,   TumVol↓, 2,   TumW↓, 2,   Weight∅, 1,  
Total Targets: 238

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   GSH↑, 1,   ROS↓, 1,   ROS↑, 1,   selenoP↑, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

mitResp↑, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,  

Cell Death ⓘ

JNK↑, 1,  

Barriers & Transport ⓘ

BBB↑, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↓, 1,   IL10↓, 1,   IL4↓, 1,   Inflam↓, 2,   TNF-α↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 2,   BioAv↝, 1,   Half-Life↓, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   cognitive↑, 1,   hepatoP↑, 3,   neuroP↑, 1,   radioP↑, 1,   RenoP↑, 1,   toxicity∅, 1,  
Total Targets: 29

Scientific Paper Hit Count for: TumCP, Tumor Cell proliferation
40 Curcumin
24 Thymoquinone
23 Quercetin
23 Shikonin
19 Magnetic Fields
18 EGCG (Epigallocatechin Gallate)
18 Berberine
18 Sulforaphane (mainly Broccoli)
17 Resveratrol
16 Baicalein
14 Silver-NanoParticles
14 Phenethyl isothiocyanate
13 Apigenin (mainly Parsley)
12 Artemisinin
12 Propolis -bee glue
11 Ashwagandha(Withaferin A)
11 Astaxanthin
11 Boron
11 Lycopene
10 Magnolol
10 Selenite (Sodium)
10 Silymarin (Milk Thistle) silibinin
10 Urolithin
9 Berbamine
9 Luteolin
8 Garcinol
8 Honokiol
7 Astragalus
7 Citric Acid
7 Bufalin/Huachansu
7 Capsaicin
7 Piperlongumine
6 Radiotherapy/Radiation
6 Boswellia (frankincense)
6 Chrysin
6 Ellagic acid
6 Phenylbutyrate
6 salinomycin
5 Betulinic acid
5 Emodin
5 Fisetin
5 Juglone
5 Rosmarinic acid
5 Vitamin K2
4 Allicin (mainly Garlic)
4 Melatonin
4 Atorvastatin
4 5-fluorouracil
4 brusatol
4 Chemotherapy
4 Disulfiram
4 Copper and Cu NanoParticles
4 Gambogic Acid
4 HydroxyTyrosol
4 Magnetic Field Rotating
4 Nimbolide
4 Cisplatin
4 Piperine
4 Ursolic acid
3 Alpha-Lipoic-Acid
3 Andrographis
3 Gemcitabine (Gemzar)
3 Aspirin -acetylsalicylic acid
3 Paclitaxel
3 chitosan
3 Butyrate
3 Photodynamic Therapy
3 diet Methionine-Restricted Diet
3 Galloflavin
3 Hydrogen Gas
3 Methylene blue
3 Oleuropein
3 Propyl gallate
3 Plumbagin
3 Pterostilbene
3 Aflavin-3,3′-digallate
3 VitK3,menadione
3 Zerumbone
2 Auranofin
2 Ascorbyl Palmitate
2 Arctigenin
2 immunotherapy
2 Docetaxel
2 Baicalin
2 Biochanin A
2 Brucea javanica
2 Bacopa monnieri
2 Caffeic acid
2 Caffeic Acid Phenethyl Ester (CAPE)
2 Celecoxib
2 Coenzyme Q10
2 Dichloroacetate
2 diet FMD Fasting Mimicking Diet
2 diet Short Term Fasting
2 Genistein (soy isoflavone)
2 Ferulic acid
2 Gallic acid
2 γ-linolenic acid (Borage Oil)
2 Graviola
2 Metformin
2 Naringin
2 Niclosamide (Niclocide)
2 Psoralidin
2 Sulfasalazine
2 Selenium
2 Salvia miltiorrhiza
2 Vitamin C (Ascorbic Acid)
2 Vitamin D3
1 2-DeoxyGlucose
1 Sorafenib (brand name Nexavar)
1 3-bromopyruvate
1 Glucose
1 SonoDynamic Therapy UltraSound
1 Zinc
1 Ajoene (compound of Garlic)
1 alpha Linolenic acid
1 Aloe anthraquinones
1 beta-glucans
1 almonertinib
1 bempedoic acid
1 Bevacizumab (brand Avastin)
1 temozolomide
1 Bromelain
1 borneol
1 Bortezomib
1 Bruteridin(bergamot juice)
1 Carnosic acid
1 Carvacrol
1 Cynanbungeigenin C (CBC) and D (CBD)
1 Cannabidiol
1 Cinnamon
1 Dichloroacetophenone(2,2-)
1 Deguelin
1 Date Fruit Extract
1 Evodiamine
1 Electrical Pulses
1 Exercise
1 Fucoidan
1 Fenbendazole
1 Vitamin E
1 Shilajit/Fulvic Acid
1 Ginkgo biloba
1 Germacranolide
1 Ginger/6-Shogaol/Gingerol
1 Siegesbeckia glabrescens
1 Hydroxycinnamic-acid
1 Hyperthermia
1 Inoscavin A
1 itraconazole
1 Ivermectin
1 Laetrile B17 Amygdalin
1 Licorice
1 Caffeine
1 doxorubicin
1 Mushroom Chaga
1 nicotinamide adenine dinucleotide
1 Bicarbonate(Sodium)
1 Oroxylin A
1 Oleocanthal
1 Proanthocyanidins
1 sericin
1 xanthohumol
1 Gold NanoParticles
1 Rutin
1 Oxaliplatin
1 Selenium NanoParticles
1 diet Plant based
1 Formononetin
1 Spermidine
1 Tumor Treating Fields
1 Arsenic trioxide
1 Wogonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:327  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page